Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery
Cette étude fait le point sur le risque de cancer du sein et de l'ovaire associé aux traitement hormonaux utilisés lors d'une transition de genre
A growing number of adult individuals in the US identify as transgender or nonbinary, and many are seeking gender-affirming therapies, including gender-affirming operations and gender-affirming hormone therapy. Examples of gender-affirming operations for transmasculine persons include chest masculinization surgery, colloquially called top surgery, in which the majority of breast tissue is removed, and bottom surgery, which includes metoidioplasty, phalloplasty, and scrotoplasty and may also include hysterectomy with or without bilateral-salpingo oophorectomy. While gender-affirming therapies are used to treat gender incongruence and/or gender dysphoria and are associated with improved mental health outcomes and overall well-being for transgender and nonbinary individuals, the potential long-term effects that these therapies may have on overall health, particularly gender-affirming hormone therapy and the risk of hormonally sensitive malignant tumors, is not currently well understood.
JAMA Surgery 2023